# Table of Contents
  * [1 Introduction](001_1_Introduction\001_1_Introduction.md)
  * [2 Methods](002_2_Methods\002_2_Methods.md)
    * [2.1 Modeling strategy](002_2_Methods\001_2_1_Modeling_strategy\001_2_1_Modeling_strategy.md)
    * [2.2 Data used](002_2_Methods\002_2_2_Data_used\002_2_2_Data_used.md)
    * [2.3 Model parameters and assumptions](002_2_Methods\003_2_3_Model_parameters_and_assumptions\003_2_3_Model_parameters_and_assumptions.md)
  * [3 Results and Discussion](003_3_Results_and_Discussion\003_3_Results_and_Discussion.md)
    * [3.1 Atazanavir final PK parameter tables](003_3_Results_and_Discussion\001_3_1_Atazanavir_final_PK_parameter_tables\001_3_1_Atazanavir_final_PK_parameter_tables.md)
    * [3.2 Atazanavir Diagnostics Plots](003_3_Results_and_Discussion\002_3_2_Atazanavir_Diagnostics_Plots\002_3_2_Atazanavir_Diagnostics_Plots.md)
    * [3.3 Atazanavir Concentration-Time profiles](003_3_Results_and_Discussion\003_3_3_Atazanavir_Concentration-Time_profiles\003_3_3_Atazanavir_Concentration-Time_profiles.md)
  * [4 Conclusion](004_4_Conclusion\004_4_Conclusion.md)
  * [References](005_References\005_References.md)
